Modulous stole all the obvious puns.

@ChaosEngine - to expand on @modulous's answer, the BBC News website has a report on the cull:

http://www.bbc.com/news/uk-30703082

It's a brilliant idea, I'd patent it. I believe it could be done (there are projector modules that would almost fit in their form factor), but only at an extraordinarily high price and with other major shortcomings like power usage that would need to be overcome.

Also, the unavoidable shadow your finger would cast but which they leave out of the mock up videos would be a problem.

I was going to post that video as a response. It's a cinematic trailer, nobody goes all crazy how WoW or the even better example he used of ESO, looks anything like the game, and people are picking on ED. Like he says, if all you are doing is delivering stuff then that's your choice. You could stick to the main bases and interdict people. Where's the people being upset at the ESO Siege trailer, makes it look like an exciting game rather than a 50 hour bore fest just to get to level 10 (a bit of an exaggeration, but seriously the leveling in that game was seriously slow and dull). I'm not expecting ED to be everything SC is, but then again all that fancy stuff with SC are add-ons and not all base game stuff. I've been happy with my ED purchase, enough so that I got a HOTAS just for it and seriously thinking of getting a TrackIR. I'm sure it'll be the same thing in SC whenever it actually ships the full game and you aren't in the dogfight module.

TONS of things cure cancer. All day, every day. Doctors have no clue what cancer is. All they can do is cut, burn, or poison and cross their fingers.

I didn't say Cannabis was THE cure. It is A cure used by thousands with amazing efficacy. Everyone is different.

Here's 60+ studies for your perusal if you insist on the superiority of western scientific research:

"Cannabis, and the cannabinoid compounds found within it, has been shown through a large cannabisplantamount of scientific, peer-reviewed research to be effective at treating a wide variety of cancers, ranging from brain cancer to colon cancer. Below is a list of over 60 studies that demonstrate the vast anti-cancer properties of cannabis.
Studies showing cannabis may combat brain cancer:
Cannabidiol (CBD) inhibits the proliferation and invasion in U87-MG and T98G glioma cells. Study published in the Public Library of Science journal in October 2013.
Tetrahydrocannabinol (THC) can kill cancer cells by causing them to self-digest. Study published in the Journal of Clinical Investigation in September 2013.
CBD is a novel therapeutic target against glioblastoma. Study published in Cancer Research in March 2013.
Local delivery of cannabinoid-filled microparticles inhibits tumor growth in a model of glioblastoma multiforme. Study published in Public Library of Science in January 2013.
Cannabinoid action inhibits the growth of malignant human glioma U87MG cells. Study published in Oncology Reports in July 2012.
Cannabidiol enhances the inhibitory effects of THC on human glioblastoma cell proliferation and survival. Study published in the Molecular Cancer Therapeutics journal in January 2010.
Cannabinoid action induces autophagy-mediated cell death in human glioma cells. Study published in The Journal of Clinical Investigation in May 2009.
Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Study published in Cancer Research in March 2008.
Cannabinoids and gliomas. Study published in Molecular Neurobiology in June 2007.
Cannabinoids inhibit gliomagenesis. Study published in the Journal of Biological Chemistry in March 2007.
A pilot clinical study of THC in patients with recurrent glioblastoma multiforme. The results were published in the British Journal of Cancer in June 2006.
Cannabidiol inhibits human glioma cell migration through an independent cannabinoid receptor mechanism. Study published in the British Journal of Pharmacology in April 2005.
Cannabinoids inhibit the vascular endothelial growth factor pathway (VEGF) in gliomas. Study published in the Journal of Cancer Research in August 2004.
Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. Study published in the Journal of Pharmacology in November 2003.
Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Study published in the Journal of Cancer Research in August 2001.
Studies showing cannabis may combat colorectal cancer:
Cannabigerol (CBG) can inhibit colon cancer cells. Study published in the Oxford journal Carcinogenesis in October 2014.
Inhibition of colon carcinogenesis by a standardised Cannabis Sativa extract with high content of CBD. Study published in Phytomedecine in December 2013.
Chemopreventive effect of the non-psychotropic phytocannabinoid CBD on colon cancer. Study published in the Journal of Molecular Medecine in August 2012.
Cannabinoids against intestinal inflammation and cancer. Study published in Pharmacology Research in August 2009.
Action of cannabinoid receptors on colorectal tumor growth. Study published by the Cancer Center of the University of Texas in July 2008.
Studies showing cannabis may combat blood cancer:
The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. Study published in the International Journal of Cancer in December 2013.
Enhancing the activity of CBD and other cannabinoids against leukaemia. Study published in Anticancer Research in October 2013.
Cannabis extract treatment for terminal acute lymphoblastic leukemia of Philadelphia chromosome (Ph1). Study published in Case Reports in Oncology in September 2013.
Expression of type 1 and type 2 cannabinoid receptors in lymphoma. Study published in the International Journal of Cancer in June 2008.
Cannabinoid action in mantle cell lymphoma. Study published in Molecular Pharmacology in November 2006.
THC-induced apoptosis in Jurkat leukemia. Study published in Molecular Cancer Research in August 2006.
Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Study published in Blood American Society of Hemmatology in July 2002.
Studies showing cannabis can combat lung cancer:
Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of Icam-1. Study published in Biochemical Pharmacology in July 2014.
Cannabinoids inhibit angiogenic capacities of endothelial cells via release of tissue inhibitor of matrix metalloproteinases-1 from lung cancer cells. Study published in Biochemical Pharmacology in June 2014.
COX-2 and PPAR-γ confer CBD-induced apoptosis of human lung cancer cells. Study published in Molecular Cancer Therapeutics in January 2013.
CBD inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. Study published in the Journal of the Federation of American Societies for Experimental Biology in April 2012.
Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non–small cell lung cancer growth and metastasis. Study published in Cancer Prevention Research in January 2011.
THC inhibits epithelial growth factor-induced (EGF) lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Study published in the journal Oncogene in July 2007.
Studies showing cannabis may combat stomach cancer:
Cannabinoid receptor agonist as an alternative drug in 5-Fluorouracil-resistant gastric cancer cells. Study published in Anticancer Research in June 2013.
Antiproliferative mechanism of a cannabinoid agonist by cell cycle arrest in human gastric cancer cells. Study published in the Journal of Cellular Biochemistry in March 2011.
Studies showing cannabis may combat prostrate cancer:
Cannabinoids can treat prostate cancer. Study published by the National Institute of Health in October 2013.
Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Study published in the British Journal of Pharmacology in December 2012.
The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications. Study published in the Indian Journal of Urology in January 2012.
Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent. Study published in Anticancer Research in November 2011.
Studies showing cannabis may combat liver cancer:
Involvement of PPARγ in the antitumoral action of cannabinoids on hepatocellular carcinoma (CHC). Study published in Cell Death and Disease in May 2013.
Evaluation of anti-invasion effect of cannabinoids on human hepatocarcinoma cells. Study published on the site Informa Healthcare in February 2013.
Antitumoral action of cannabinoids on hepatocellular carcinoma. Study published in Cell Death and Differentiation in April 2011.
Studies showing cannabis may combat pancreatic cancer:
Cannabinoids inhibit energetic metabolism and induce autophagy in pancreatic cancer cells. Study published in Cell Death and Disease in June 2013.
Cannabinoids Induce apoptosis of pancreatic tumor cells. Study published in Cancer Research in July 2006.
Studies showing cannabis may combat skin cancer:
Cannabinoid receptor activiation can combat skin cancer. Study published by the National Institute of Health in October 2013.
Cannabinoids were found to reduce skin cancer by 90% in just 2 weeks. Study published in the Journal of Pharmacy and Pharmacology in July 2013.
Cannabinoid receptors as novel targets for the treatment of melanoma. Study published in the Journal of the Federation of American Societies for Experimental Biology in December 2006.
Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. Study published in the Journal of Clinical Investigation, in January 2003.
Studies showing cannabis may combat other types of cancer:
Bladder: Marijuana reduces the risk of bladder cancer. Study published in the Medscape site in May 2013.
Kaposi sarcoma: Cannabidiol inhibits growth and induces programmed cell death in Kaposi sarcoma–associated herpesvirus-infected endothelium. Study published in the journal Genes & Cancer in July 2012.
Nose, mouth, throat, ear: Cannabinoids like THC inhibit cellular respiration of human oral cancer cells. Study by the Department of Pediatrics at the State University of New York, published in June 2010.
Bile duct: The dual effects of THC on cholangiocarcinoma cells: anti-invasion activity at low concentration and apoptosis induction at high concentration. Study published in Cancer Investigation in May 2010.
Ovaries: Cannabinoid receptors as a target for therapy of ovarian cancer. Study published on the American Association for Cancer Research website in 2006.
Preparation and characterisation of biodegradable microparticles filled with THC and their antitumor efficacy on cancer cell lines. Study published in the Journal of Drug Targeting in September 2013.
CBD Cannabidiol as a potential anticancer drug. Study published in the British Journal of Pharmacology in February 2013.
Cannabinoids as anticancer modulators. Study published in the Progress in Lipid Research journal in January 2013.
CBD inhibits angiogenesis by multiple mechanisms. Study published in the British Journal of Pharmacology in November 2012.
Towards the use of cannabinoids as antitumour agents. Study published in Nature in June 2012.
Cannabinoid-associated cell death mechanisms in tumor models. Study published in the International Journal of Oncology in May 2012.
Cannabinoids, endocannabinoids and cancer. Study published in Cancer Metastasis Reviews in December 2011.
The endocannabinoid system and cancer: therapeutic implication. Study published in the British Journal of Pharmacology in July 2011.
This list was compiled in part by Alchimiaweb.com.
– TheJointBlog"

@modulous I believe that if they both had a flush that the spades flush would take it. I'm not 100% sure about how the rules apply to the world series of poker, but, traditionally, the suits do have value. I believe the order is:
Spades
Hearts
Diamonds
Clubs
The value is alphabetical.

The new spacex module will make this look like an old 1920's model T vs. a BMW in terms of crew space and comfort

Seconding Artician. The brain evolved by natural selection, just like the rest of the body. It has built in biases and modules that vary genetically. Look at the wide variety of personalities in dog breeds, for example. In humans, the big five personality traits are estimated to be about 50% heritable based on twin studies.

Gattaca is a good movie and Brave New World is a good book, but they should not be taken as the ends of some slippery slope that any eugenic policy inevitably leads to. I think it's unfortunate that so much fear of eugenics is propagated by dystopian fictions like those. Eugenics can be done in a humane way that respects all individual rights. For instance:

1. a system of incentives for highly successful people to have more children or donate to sperm banks.

2. Universal single-payer healthcare, providing among other things free condoms and birth control pills to all, so that the use of contraception will not be so much inversely correlated with income as it has been from 1850 to the present when the poor often couldn't afford it (and it's a demonstrable fact that on average the poor tend to have lower intelligence partly due to genetics)

Even such modest, individual rights respecting policies, if phrased in terms of benefiting the gene pool, are political suicide because people are still afraid of imaginary slippery slopes leading to Hitler. Most of the US is still in denial of the implications of biological science, for reasons that speak well of them, but it's time to grow up and get over that habit of Godwinizing any attempt to improve the gene pool regardless of whether it infringes individual rights.

Or maybe lots of people people don't actually believe that, but are reluctant to say otherwise: https://www.youtube.com/watch?v=B0W9sSqeJnA

Seems kind of monstrous to lock your employee in with a knife wielding psycho just to prevent him from stealing some cash. Maybe there's something I'm missing, but I agree with modulous that she doesn't seem to be protected by anything.

You are thinking about QAM, Quadrature Amplitude Modulation. Thats an interesting question because QAM essentially produces the same results that the prof talks about in this video. By using interesting ways to change the beat and phase of a single carrier, one can represent a whole array of numbers greater than just a 1 or a zero with a single pulse, case in point.

In QAM, lets just use the easy example of QAM, QPSK (4QAM), where there are 4 possible binary positions for any given 'carrier' signal at a known frequency.

By shifting both phase and amplitude, you can get a 0, 1, 2 or 3, where each position represents a power of 2, up to a total value of 16 unique numbers.

Rather than just a 0 or a 1, you can have 0 through to 15. However doing this requires both a timeslot, and a known carrier window.

The fastest the QAM transmitter can encode onto a carrier is limited by the nyquist rate, that is, less than half the frequency which the receiver can sample at its fastest rate (on the remote end). As you increase the speed of the encoding, you also increase the error rate, and introduce more noise into the base carrier signal, in turn, reducing your effective available bandwidth.

So it then becomes a balancing act, do I want to encode faster, or do I want to increase my constellation density? The obvious answer is the one we went with, increase in constellation density.

There are much more dense variants, I think the highest ive heard of was 1024 QAM, where a single carrier of 8MHz wide could represent 1024 bits (1,050,625 unique values for a given 'pulse' within a carrier).

I actually had a lot more typed out here, but the maths that goes into this gets very ugly, and you have to account for noise products that are introduced as you increase both your transmission speed, and your receiver sensitivty, thus lowering your SNR, reducing your effective bandwidth for a given QAM scheme.

So rather than bore you with the details, the Shannon Hartley theorem is the hard wired physical limitation.

Think of it as an asymptote, that QAM is one method of trying to milk the available space of.

You can send encoded pulses very fast, but you are limited by nyquist, and your receivers ability to determine noise from signal.

The faster you encode, the more noise, the less effective bandwidth....and so begins the ritule of increasing constellation density, and receivers that can decode them....etc....

There is also the aspect of having carriers too close to one another that you must consider. If you do not have enough of a dead band between your receivers cut off for top end, and the NEXT carrier alongs cutoff for deadband at its LOW end, you can induce what is known as a heterodyne. These are nasty, especially so when talking about fibre, as the wavelengths used can cause a WIDE BAND noise product that results in your effective RF noise floor to jump SUBSTANTIALLY, destroying your entire network in the process.

So not only can you not have a contiguous RF bandwidth of carriers, one directly after another...if you try and get them close, you end up ruining everyones day.

I am sure there will be newer more fancy ways to fill that spectrum with useable numbers, but I seriously doubt they will ever go faster than the limit I proposed earlier (unless they can get better SNR, again that was just a stab in the dark).

It gives you a good idea of how it works though.

If you want to read more on this, I suggest checking wikipedia for the following;

Shannon Hartley theorem.
Nyquist Rate
Quadrature Phase Shift Key
Quadrature Amplitude Modulation
Fibre Optic Communication Wavelengths
Stimulated Brillouin Scattering
Ebrium Doped Fibre Amplifiers

Not necessarily...

1) This truck is broadcasting the song over the CB.
2) This truck is broadcasting the song with a wireless FM modulator.

Personally, #1 seems more likely.

I am under impressed with Hearth Stone. I much prefer Faëria... However HS is well polished and they have a nice balance between the free to play and items to purchase. I might put it ahead of Infinity Wars, as IW tends to be overly complex and deep when many times I want a simple fun game, I go back to Faëria for my more complex type game... I would also put it ahead of Magic 2014, but then I was never a Magic fan... Android Netrunner if that came in digital form (aside from the OCTGN module)... then I'd be in trouble... as would the digital card game world as Fantasy Flight's Netrunner is perhaps the best card game out there...

The thing is though, the way it's described in this video. Unless I am totally off in LaLa land concerning electronics and how they hook together. There's just no way his power grid section is going to work with 4 connectors. Let's assume 4 connectors is all anything needs, then how do you swap out pieces and re-arrange them to your desire and still have the connections end up to where they hook up properly to others without replacing the grid backing?

So if you need a grid backing for each arrangement, you're not helping your cause.

He's basically saying the grid back is your motherboard, which needs a bare minimum of things to function and it designed for them to hook up in certain ways with a myriad of different pin configurations. And you think of how many things in the PC market aren't QUITE compatible, like they do hokey things even though standards wise they should be compatible....so you have to look at the MFG sites to see if they have tested it with XYZ....

I mean hell anything PC is kind of throwaway as it is now, they cycle in new standards so fast. The only main difference is you can build it like you want it, so you're less likely to replace it soon....and if most things break you can replace them to keep from throwing everything else out...within some period of time usually 5-6 years would be a good "hope" for things like motherboards, cpu if you're right on the cutting edge. 1-3 if you buy them later in their life cycle.

So, maybe instead of a blok style phone, they need a design where shops could essentially build you a phone around a core module for each phone carrier. Then you wouldn't have 8 bazillion phones being manufactured each year and being tossed. You'd have 20 bazillion parts that could be used as needed within a few years to fit someone's needs/wants.

But, it won't happen. And they'll say it's because they are keeping costs down by doing it how they do it now....you know...not because it helps maintain bigger profit margins or anything.........never.

CBD possesses sedative properties (Carlini and Cunha, 1981), and a clinical
trial showed that it reduces the anxiety and other unpleasant psychological
side effects provoked by pure THC (Zuardi et al. 1982). CBD modulates the
pharmacokinetics of THC by three mechanisms: (1) it has a slight affinity for
cannabinoid receptors (Ki at CB1 = 4350 nM, compared to THC = 41 nM,
Showalter et al. 1996), and it signals receptors as an antagonist or reverse agonist
(Petitet et al. 1998), (2) CBD may modulate signal transduction by perturbing
the fluidity of neuronal membranes, or by remodeling G-proteins that
carry intracellular signals downstream from cannabinoid receptors, and (3)CBD
is a potent inhibitor of cytochrome P450 3A11 metabolism, thus it blocks the
hydroxylation of THC to its 11-hydroxy metabolite (Bornheim et al. 1995).
The 11-hydroxy metabolite is four times more psychoactive than unmetabolized
THC (Browne and Weissman 1981), and four times more immunosuppressive
(Klein et al. 1987).
CBD provides antipsychotic benefits (Zuardi et al. 1995). It increases dopamine
activity, serves as a serotonin uptake inhibitor, and enhances norepinephrine
activity (Banerjee et al. 1975; Poddar and Dewey 1980). CBD protects
neurons from glutamate toxicity and serves as an antioxidant, more potently
than ascorbate and α-tocopherol (Hampson et al. 1998). Auspiciously, CBD
does not decrease acetylcholine (ACh) activity in the brain (Domino 1976;
Cheney et al. 1981). THC, in contrast, reduces hippocampal ACh release in
rats (Carta et al. 1998), and this correlates with loss of short-term memory consolidation.
In the hippocampus THC also inhibits N-methyl-D-aspartate (NMDA)
receptor activity (Misner and Sullivan 1999; Shen and Thayer 1999), and
NMDA synaptic transmission is crucial for memory consolidation (Shimizu et
al. 2000). CBD, unlike THC, does not dampen the firing of hippocampal cells
(Heyser et al. 1993) and does not disrupt learning (Brodkin and Moerschbaecher
1997).
Consroe (1998) presented an excellent review of CBD in neurological disorders.
In some studies, it ameliorates symptoms of Huntington’s disease, such
as dystonia and dyskinesia. CBD mitigates other dystonic conditions, such as
torticollis, in rat studies and uncontrolled human studies. CBD functions as an
anticonvulsant in rats, on a par with phenytoin (Dilantin, a standard antiepileptic
drug).
CBD demonstrated a synergistic benefit in the reduction of intestinal motility
in mice produced by THC (Anderson, Jackson, and Chesher 1974). This
may be an important component of observed benefits of cannabis in inflammatory
bowel diseases.

--"Cannabis and Cannabis Extracts:
Greater Than the Sum of Their Parts?
John M. McPartland
Ethan B. Russo"

Usil no longer needs the weirding module!